AMAlberto J. Montero

Alberto J. Montero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alberto J. Montero has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Value Assessment Frameworks in the United States: A Call for Patient Engagement

    by Vakaramoko Diaby, Askal A. Ali, Alberto J. Montero


  • Analysis of Origins of Admission for Solid Tumor Oncology Inpatients: Disease Severity and Outcomes

    by Christopher E. Wee, Lindsey M. Goodman, Leticia Varella, Lisa A. Rybicki, Alberto J. Montero, Bassam N. Estfan, Carolyn H. Best, James P. Stevenson

    Purpose: Hospital transfers may affect clinical outcomes. Evaluation of admission by source of transfer, time of admission, and provider type may identify opportunities to improve inpatient outcomes. Methods: We reviewed charts of patients admitted to the solid tumor oncology service between July and December 2014 from the Cleveland Clinic Foundation (CCF) Main Campus emergency department (ED), CCF Regional EDs, outside hospital (OSH) ED, OSH inpatient services, and CCF outpatient clinics. Data collected included time of admission, mortality and severity risk scores, and provider type. Risk factors were assessed for clinical outcomes, including activations of the Adult Medical Emergency Team, intensive care unit transfers, in-hospital mortality, and length of stay (LOS). Results: Five hundred admissions were included. OSH inpatient transfers had significantly higher disease severity compared with all other origins of admission. OSH inpatient transfers demonstrated significantly longer LOS compared with all other origins of admission, and higher mortality rates compared with the outpatient direct admits and CCF Main Campus ED admits. After adjusting for disease severity and risk of mortality, OSH ED patients remained at higher risk for Adult Medical Emergency Team activation, OSH inpatient transfers had the longest LOS, and CCF Main Campus ED patients had the lowest risk of mortality. Time of admission and provider type were not associated with any of the outcomes. Conclusion: Oncology inpatients transferred from an outside health care facility are at higher risk for adverse outcomes. The magnitude of difference is lessened, but still significant, after adjustment for disease severity and risk of mortality.

  • Multi-institutional comparison of breast cancer risk stratification by 70-gene signature and 21-gene assay.

    by David J. Dabbs, Charles E. Cox, Steven Shivers, Nathaniel Bouganim, Jamil Asselah, Ramy Saleh, Lisa Eileen Blumencranz, Alberto J. Montero, Benjamin C. Calhoun, Tina Treece, et al.

    522 Background: Breast cancer risk stratification with the 70-gene signature (70-GS) provides a binary low risk (LR) or high risk (HR) result; by contrast the 21-gene assay (21-GA) provides LR, intermediate (IR), and HR results. Results from these two assays were compared for 769 patients from 5 institutions. Methods: The study included patients from McGill University (n = 86), UPMC (n = 437), USF (n = 135), Morton Plant North Bay Hospital (n = 79), and Cleveland Clinic (n = 32, all 21-GA IR). Results: With the 70-GS, 487 (63%) patients had a LR and 282 (37%) patients had a HR result. Excluding 32 cases selected for 21-GA IR results (n = 737), the 21-GA gave 369 (50%), 250 (34%), and 118 (16%) patients with LR, IR, and HR scores, respectively. Using the TAILORx cutoff, there were 134 (18%), 432 (59%), and 171 (23%) patients with LR, IR, and HR scores, respectively. There were 329 (45%) and 486 (66%) patients who were not classified in the same risk category by both assays using the clinical and TAILORx cutoffs for IR, respectively. Conclusions: In a large multi-institutional study the 70-GS and 21-GA results were discordant in 45-66% of patients, and the proportion of patients with a 21-GA score in the IR range varied from 34-59%. The 70-GS provided clinically actionable results for all patients. [Table: see text]


  • Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

    by Vakaramoko Diaby, Georges Adunlin, Askal A. Ali, Simon B. Zeichner, Gilberto de Lima Lopes, Christine G. Kohn, Alberto J. Montero

    Purpose Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). Patients and methods We constructed a Markov model to assess the cost-effectiveness of four different HER2 targeted treatment sequences in patients with HER2-positive mBC treated in the U.S. The model followed patients weekly over their remaining life expectancies. Health states considered were progression-free survival (PFS) 1st to 3rd lines, and death. Transitional probabilities were based on published phase III trials. Cost data (2015 US dollars) were captured from the U.S. Centers for Medicare and Medicaid Services (CMS) drug payment table and physician fee schedule. Health utility data were extracted from published studies. The outcomes considered were PFS, OS, costs, QALYs, the incremental cost per QALY gained ratio, and the net monetary benefit. Deterministic and probabilistic sensitivity analyses assessed the uncertainty around key model parameters and their joint impact on the base-case results. Results The combination of trastuzumab, pertuzumab, and docetaxel (THP) as first-line therapy, trastuzumab emtansine (T-DM1) as second-line therapy, and lapatinib/capecitabine third-line resulted in 1.81 QALYs, at a cost of $335,231.35. The combination of trastuzumab/docetaxel as first line without subsequent T-DM1 or pertuzumab yielded 1.41 QALYs, at a cost of $175,240.69. The least clinically effective sequence (1.27 QALYs), but most cost-effective at a total cost of $149,250.19, was trastuzumab/docetaxel as first-line therapy, T-DM1 as second-line therapy, and trastuzumab/lapatinib as third-line therapy. Conclusion Our results suggest that THP as first-line therapy, followed by T-DM1 as second-line therapy, would require at least a 50 % reduction in the total drug acquisition cost for it to be considered a cost-effective strategy.


  • Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer

    by Shruti R. Tiwari, Prasun Mishra, Paola Raska, Benjamin Calhoun, Jame Abraham, Halle Moore, G. Thomas Budd, Alicia Fanning, Stephanie Valente, Robyn Stewart, et al.

    Background Pertuzumab is FDA approved in the preoperative setting in combination with trastuzumab and chemotherapy, in women with nonmetastatic HER2 + breast cancer. The TRYPHAENA trial (n = 77) reported a pathologic complete response rate (pCR), i.e., ypT0ypN0, of 52 % in patients treated with neoadjuvant (docetaxel, carboplatin, trastuzumab, & pertuzumab) TCH-P. Aside from this study, there is limited information regarding the safety and efficacy of TCH-P in the neoadjuvant setting. Our goal was to evaluate the safety and efficacy of neoadjuvant TCH-P in a non-clinical trial setting. Materials and methods Cancer data registry was utilized to identify patients with HER2 + nonmetastatic breast cancer that received neoadjuvant TCH-P. pCR was defined as the absence of invasive or noninvasive cancer in breast and lymph nodes, i.e., ypT0ypN0. Results 70 patients with a median age of 52 years met our inclusion criteria. Clinical staging was I-8.5 %; II-68.5 %; and III-22.8 %. 60 % of patients had hormone receptor (HR)-positive tumors. 23 % (16/71) of patients required dose reduction for rash, diarrhea, neuropathy, or thrombocytopenia. Overall, no patients developed grade 3–4 left ventricular systolic dysfunction(LVSD); an asymptomatic reduction in LVEF of >10 % was observed in three patients. The overall observed pCR rate was 53 %. As expected, the pCR rate was higher in patients with HR-negative breast cancer than for patients with HR+ disease: 69 % (20/29) vs. 42 % (17/41), respectively. The axillary downstaging rate was approximately 53 % (19/36). Conclusion Neoadjuvant TCH-P, in a nonclinical trial setting, was associated with a pCR rate of 53 % similar the reported rate in TRYPHAENA. Toxicity was manageable, with no patients experiencing symptomatic heart failure.


  • Use of imaging studies for early-stage breast cancer at Cleveland Clinic.

    by Sanghee Hong, Leticia Varella, Katherine Tullio, Halle C. F. Moore, G. Thomas Budd, Stephen R. Grobmyer, Alberto J. Montero, Gary Schnur, Jame Abraham

    E18217 Background: Use of staging imaging (SI), including CT, PET and bone scans, is not routinely recommended in stage I-IIA breast cancer patients (ESBCP) in the absence of signs or symptoms of metastatic disease. Consistent with NCCN guidelines, the evidence-based Care Path developed at our institution discourages routine SI in this population. We reviewed the use of SI in ESBCP before and after implementation of Care Path. Methods: An IRB-approved retrospective review of newly diagnosed ESBCP seen at Cleveland Clinic between January 2013 and June 2015 was performed based on institutional cancer database. JMP10 was used for statistical analysis. All p-values were 2-sided. Results: We identified 345 ESBCP seen between January 2013 and December 2014 as the pre-Care Path group (Pre-CP) and 246 ESBCP seen between July 2014 and June 2015 as the post-Care Path group (Post-CP). We excluded 6 patients in each group due to ambiguity in the purpose of SI. Median age was 62 in the Pre-CP and 63 in the Post-CP; > 99% were female in both cohorts; most were stage IA in both cohorts. SI was performed in 19% of patients in Pre-CP and 16% of Post-CP. Only 8% of patients in Pre-CP (N = 26) and 6% in Post-CP (N = 12) had SI judged as “routine.” Specific indications included the presence of symptoms or lab abnormalities (4% in Pre-CP; 6% in Post-CP), follow-up of abnormal imaging studies done prior to diagnosis or after breast MRI (5% in Pre-CP; 2% in Post-CP), other indicated cancer screening/staging of concurrent cancer (1% in both groups), and surgical indications besides pre-surgical planning (1% in Pre-CP; < 1% in Post-CP). There were no statistical differences in SI between Pre-CP and Post-CP. Of SI done “routinely,” 11% (N = 4) had positive findings, all of which were later found to be false-positives. In total, 20% (N = 12) of imaging studies done for other indications were abnormal, with 17% (N = 2) of these abnormal findings confirmed as metastatic breast cancer. Conclusions: Our results support continued use of current imaging guidelines. The use of imaging studies for staging in ESBC was appropriately low before and after the implementation of Care Path in our institution, reflecting good compliance with current guidelines.

  • Predictors of readmission for hospitalized cancer patients: A cohort study.

    by Shiva Shrotriya, Davendra Sohal, Alberto J. Montero, Alok A. Khorana

    E18185 Background: Reducing unplanned hospital readmissions is a national policy priority aimed at improving health care quality. It is unclear if readmissions are preventable in cancer patients with ongoing complexities of care. We conducted a retrospective cohort study to identify rates and predictors of readmission among cancer inpatients. Methods: We conducted a retrospective cohort study including all consecutive admissions with between January and December 2013 at the general medical oncology floor Cleveland Clinic. We conducted logistic regression analyses to identify predictors of readmission. Results: There were 1210 admissions. Of these, 262 inpatients were readmitted within 30 days (21.6%). Of the readmitted patients, 57% were females; mean age (±SD) was: 63 ± 12.2 years; 72% were Caucasians and 23% were African Americans. Median (range) length of stay among readmitted patients was 4(0-46) days. Common cancers were renal (72%), lymphoma (22%), lung (21%) and breast (17%). On univariate analysis, those with renal (RR: 1.62; 1.33-2.05) and gastric (RR: 1.04; 0.99-1.09) cancers were at higher readmission risk. Comorbidities such as respiratory illness (RR: 3.32; 2.27-5.83), anemia (RR: 2.24; 1.62-3.32), infections (RR: 1.86; 1.44-2.39), hypertension (RR: 1.40; 1.10-1.81), venous thromboembolism; VTE (RR: 1.31; 1.16-1.50), diabetes (RR: 1.21; 1.10-1.36), hepatic diseases (RR: 1.18; 1.04-1.35), anxiety (RR: 1.14; 1.02-1.30), congestive heart failure (RR: 1.10; 1.02-1.87), pressure ulcers (RR: 1.12; 1.04-1.22) cerebrovascular diseases (RR: 1.12; 1.05-1.21) increased ALT (RR: 1.05; 0.99-1.11) and increased AST (RR: 1.05; 0.99-1.11) were also associated with increased readmission risk on univariate analysis. On multivariate analysis, only infections (OR: 2.01; 1.06-3.80) and respiratory illnesses (OR: 4.21; 1.58-11.19) remained independent predictors of readmission. Conclusions: Hospitalized cancer patients are at high risk of readmission. Comorbidities, particularly infections and respiratory illnesses, are independent predictors of readmission. Interventions aimed at reducing readmissions should target this high-risk population to reduce health care resource utilization and burden to patients.

  • Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.

    by Shruti Rakesh Tiwari, Paola Raska, Halle C. F. Moore, Hamid Emamekhoo, Jame Abraham, G. Thomas Budd, Alberto J. Montero

    594 Background: HER-2 overexpression confers a more aggressive tumor phenotype in breast cancer, even in stage 1 disease. The large adjuvant trastuzumab trials excluded patients with node-negative tumors smaller than 1 cm. Subset analysis of one trial suggested patients with tumors 1–2 cm in size derived at least as much clinical benefit from adjuvant trastuzumab as did the overall cohort.It is currently unknown whether patients with T1a-T1bN0 HER-2+ tumors should routinely receive adjuvant chemotherapy and trastuzumab. Our goal was to examine clinical outcomes in patients with small HER2+ tumors treated at Cleveland Clinic (CC) to help guide treatment decisions. Methods: Cancer data registry was utilized to identify patients with stage I HER2+ cancer treated with or without trastuzumab and chemotherapy at CC after 2006. Patient charts were reviewed for recurrence and survival information. Disease-free survival (DFS) was defined as time from date of diagnosis to relapse, second primary cancer or death, whichever occurred first. Results: 255 patients met our inclusion criteria with median age of 59 years. Median follow up was 4.8 years (range: 0.1 to 9.7 years). 5 year DFS was 92.8% (95% CI-89-96%). DFS was 95% (95%CI-91-99%) and 89%(95% CI 81-96%) in patients treated with and without trastuzumab and chemotherapy respectively (p < 0.01). This difference was consistent across all tumor sizes (T1a, T1b, T1c). The probability of receiving chemotherapy was associated with tumor size- 79% of T1c tumors and only 54% of T1a/b tumors had chemotherapy (p < 0.001). Patients < 55 years of age with T1a/b tumors had worse DFS than patients with T1c tumors (p < 0.05) with a 5 year DFS of 87% (95% CI 77%-99%) and 98% (95% CI 93% – 100%) respectively. Conclusions: Chemotherapy with trastuzumab use was associated with improved DFS in patients with stage I HER2+ tumors. Among younger patients, we observed inferior DFS in patients with small, node-negative cancers(T1a/b), who were less likely to receive trastuzumab and chemotherapy, compared to patients with larger tumors(T1c). Use of trastuzumab and chemotherapy should be strongly considered in younger patients with T1a/b HER2+ tumors.

  • Reducing Unplanned Medical Oncology Readmissions by Improving Outpatient Care Transitions: A Process Improvement Project at the Cleveland Clinic

    by Alberto J. Montero, James Stevenson, Amy E. Guthrie, Carolyn Best, Lindsey Martin Goodman, Shiva Shrotriya, Abdel-Ghani Azzouqa, Armida Parala, Ruth Lagman, Brian J. Bolwell, et al.

    Purpose: Reducing 30-day unplanned hospital readmissions is a national policy priority. We examined the impact of a quality improvement project focused on reducing oncology readmissions among patients with cancer who were admitted to palliative and general medical oncology services at the Cleveland Clinic. Methods: Baseline rates of readmissions were gathered during the period from January 2013 to April 2014. A quality improvement project designed to improve outpatient care transitions was initiated during the period leading to April 1, 2014, including: (1) provider education, (2) postdischarge nursing phone calls within 48 hours, and (3) postdischarge provider follow-up appointments within 5 business days. Nursing callback components included symptom management, education, medication review/compliance, and follow-up appointment reminder. Results: During the baseline period, there were 2,638 admissions and 722 unplanned 30-day readmissions for an overall readmission rate of 27.4%. Callbacks and 5-day follow-up appointment monitoring revealed a mean monthly compliance of 72% and 78%, respectively, improving over time during the study period. Readmission rates declined by 4.5% to 22.9% (P < .01; relative risk reduction, 18%) during the study period. The mean direct cost of one readmission was $10,884, suggesting an annualized cost savings of $1.04 million with the observed reduction in unplanned readmissions. Conclusion: Modest readmission reductions can be achieved through better systematic transitions to outpatient care (including follow-up calls and early provider visits), thereby leading to a reduction in use of inpatient resources. These data suggest that efforts focused on improving outpatient care transition were effective in reducing unplanned oncology readmissions.


  • Effects of admission (adm) source, time, and provider on inpatient (inpt) oncology (onc) outcomes at the Cleveland Clinic Foundation (CCF).

    by Wee Christopher, Lindsey Martin Goodman, Lisa A. Rybicki, Alberto J. Montero, Bassam N. Estfan, Carolyn Best, James Stevenson

    140 Background: The quality of care transfers is known to influence clinical outcomes. In an inpt onc setting at a major tertiary care referral center, patient (pt) adm originate from many different areas and times. A detailed evaluation of onc adm by source of transfer, admission time, and provider type, may identify opportunities to improve inpt clinical outcomes. Methods: We retrospectively reviewed all adm to the inpt solid tumor onc service from July - December 2014 from CCF regional hospital emergency departments (ED), outside hospital (OSH) ED, OSH inpt services, and CCF outpt clinics. Pts were excluded if the adm was planned or if admitted from the CCF Main Campus ED. Data collected included pt and encounter characteristics and provider type (house-staff or nocturnal hospitalist). Clinical outcomes, including activation of the adult medical emergency team (AMET), ICU transfers, length of stay (LOS), and in-hospital mortality were compared using chi-squared test; ECOG PS and LOS with the Kruskal-Wallis tests and Wilcoxon rank sum test. Results: A total of 413 unique pt admissions were reviewed. 213 were included after exclusion criteria were applied. The probability of AMET activation, mortality, and LOS differed by origin of transfer. Pts admitted from CCF regional EDs had the lowest median LOS and no deaths. OSH int transfers demonstrated significantly higher mortality vs other origins of transfer. Pts whose first orders were placed after 5pm had no significant differences in AMET activation, ICU transfers, LOS, or mortality vs daytime adm. There were no differences in adverse outcomes by the type of admitting provider. Conclusions: Onc inpts transferred from an outside healthcare setting were at highest risk for adverse outcomes (AMETs, increased LOS, and mortality) include those originating from OSH inpt services. Process and communication interventions focused on transfers from outside inpt facilities may improve safety and outcomes in this population. [Table: see text]